Bortezomib: a new therapeutic option for POEMS syndrome
- 4 January 2010
- journal article
- case report
- Published by Wiley in European Journal of Haematology
- Vol. 84 (2) , 175-177
Abstract
Objective: POEMS syndrome with its classical five findings (Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin changes) is a rare multisystem disease. Proinflammatory and proangiogenic cytokines play important roles in its pathogenesis. Treatment options are still debated. Methods: We present a 65‐year‐old man with POEMS syndrome who was successfully treated with bortezomib. Results: After seven cycles of this protocol, serum M protein level declined to normal range, and near‐to‐complete remission was achieved. His symptoms of polyneuropathy improved dramatically. Conclusion: Bortezomib may be an effective and safe therapeutic option for patients with POEMS syndrome.Keywords
This publication has 10 references indexed in Scilit:
- Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndromeJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndromeAnnals of Oncology, 2008
- POEMS syndromeBlood Reviews, 2007
- Treatment of POEMS syndrome with bevacizumabHaematologica, 2007
- Vascular endothelial growth factor promoted endothelial progenitor cell mobilization into the peripheral blood of a patient with POEMS syndromeHaematologica, 2007
- Lenalidomide therapy in a patient with POEMS syndromeBlood, 2007
- Bevacizumab therapy for POEMS syndromeBlood, 2006
- Bevacizumab therapy for POEMS syndromeBlood, 2005
- Bortezomib: A valuable new antineoplastic strategy in multiple myelomaActa Oncologica, 2005
- Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literatureBlood, 2004